MAPT and Alzheimer disease: In 2018, Litvinchuk et al. showed the higher expression of C3 and C3AR1 in human brains with hyperphosphorylated tau and identified p-STAT3 as the direct downstream effector of the C3-C3AR signaling with detrimental effects in AD [14].